Evolus Inc. lost a third of its value after lower-than-expected second quarter results, reflecting weakened demand within the U.S. aesthetics market.
The Newport Beach-based aesthetics company reported its adjusted non-GAAP loss from operations widened to $7.9 million, up from profit of $1.1 million in the year ago quarter. Revenue of $69.4 million missed the consensus estimate of $82 million.
“Our second quarter results came in below expectations, reflecting one of the most challenging market environments we’ve seen in recent years,” Evolus Chief Executive David Moatazedi said in an Aug. 5 earnings call.
Evolus slashed its 2025 full-year revenue guidance to $295 million to $305 million, down from its initial outlook of $345 million to $355 million.
The company’s results were consistent with overall market trends of a decline in procedural volume in the first half of the year, Moatazedi said.
In the four trading sessions after the report, shares fell 35% to $5.71, hitting a five-year low with a market cap of $381 million (Nasdaq: EOLS).
Aesthetics Market Indicator
One key indicator of weakened industry demand is Allergan Aesthetics, the aesthetics unit of Chicago biopharmaceutical giant AbbVie Inc. and leader in the aesthetics space.
Global net revenues for the aesthetics portfolio decreased 8.1% to $1.3 billion in the second quarter with sales declines for both Botox and Juvederm.
“Aesthetics was soft as anticipated and continues to be hampered by macro headwinds that are persisting, so it’s prudent to remain cautious with that franchise though ABBV is still optimistic it will turn around longer-term,” Raymond James analysts Gary Nachman and Denis Reznik wrote in a note to investors.
It’s a continued trend from first quarter where the unit saw sales fall 11.7% to $1.1 billion.
Carrie Strom headed the unit for five years until she unexpectedly left in April.
Despite these challenges, long-term prospects “remain attractive given high consumer interest and low penetration rates for facial injectables,” AbbVie officials said in the company’s first quarter earnings call.
ICU Medical, Masimo Down on Q2 Earnings
Other local healthcare companies this month reported second-quarter earnings causing shares to fall.
San Clemente-based ICU Medical Inc., a maker of medical infusion systems, on Aug. 7 reported revenue of $548.9 million, above the analyst estimate of $539.7 million (Nasdaq: ICUI).
ICU Medical’s stock fell 13% to $112.85 and a $2.7 billion market cap the day after earnings.
“Despite strength in the underlying business (ex tariffs, guidance has trended higher), tariff concerns have weighed on the stock,” Raymond James analyst Jayson Bedford wrote in a note to investors.
The firm still issued a Strong Buy rating for the company, citing new product launches and ongoing efforts to optimize cost structure.
Shares in Masimo Corp. were also down 12% following the company’s second quarter results on Aug. 5.
The drop caught some analysts off guard given the company’s earnings, which exceeded expectations. Some have pointed to the 40% decrease in new contracts as a source for the stock falling.
“This figure is being termed as representative of business health and a leading indicator of future revenue, but we’re strongly of the opinion that bears are attempting to casually connect dots… We’re defending, buy the dip,” Piper Sandler analysts Jason Bednar and Joseph Downing wrote in a note to investors.
